BriaCell Therapeutics Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: Mar 12, 2025 · CIK: 1610820
Sentiment: neutral
Topics: disclosure, financials, corporate-actions
Related Tickers: BCTX
TL;DR
BriaCell Therapeutics filed an 8-K on March 12, 2025, with Reg FD disclosures and financials.
AI Summary
BriaCell Therapeutics Corp. filed an 8-K on March 12, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing provides updates on regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and disclosures, not indicating any immediate operational or financial distress.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- March 12, 2025 (date) — Date of report
- June 13, 2014 (date) — Date of name change
FAQ
What specific Regulation FD disclosures are being made in this 8-K filing?
The filing indicates a Regulation FD Disclosure item, but the specific details of the disclosure are not provided in the provided text snippet.
What are the key exhibits included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific exhibits are not detailed in the provided text.
When did BriaCell Therapeutics Corp. change its name from Ansell Capital Corp.?
The company changed its name from Ansell Capital Corp. on June 13, 2014.
What is the principal executive office address for BriaCell Therapeutics Corp.?
The principal executive office is located at Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1.
What is the Standard Industrial Classification code for BriaCell Therapeutics Corp.?
The SIC code for BriaCell Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 12, 2025 regarding BriaCell Therapeutics Corp. (BCTXZ).